Proteomics International Laboratories (PIQ) Bell Potter Healthcare Conference 2025 summary

Product Portfolio and Market Positioning

• Four first-in-class diagnostic tests target diabetic kidney disease, esophageal cancer, endometriosis, and oxidative stress, validated in large clinical studies and addressing significant unmet needs.

• Tests are developed on immunoassay and mass spectrometry platforms, patented, and offer high margins, with a customer-driven strategy focused on primary care and GP clinics.

• Digital platform supports direct patient and physician engagement, attracting global key opinion leaders and strategic partners.

• Commercial infrastructure and labs established in the U.S. and Australia, with blood collection networks operational.

• Funding, team, and certifications are in place to support ongoing launches and expansion.

Market Launch, Sales, and Reimbursement

• PromarkerD for diabetic kidney disease is live in Australia and California, with reimbursement pricing pending and expected to be set at $390 per test.

• Early U.S. sales are self-pay, with insurance reimbursement to follow once pricing is finalized; Medicare coverage will be pursued nationwide after local determination.

• Esophageal cancer and endometriosis tests are launching in Australia, with U.S. launches to follow; both address markets lacking non-invasive diagnostics.

• Strategic focus is on building awareness, growing test volumes, and securing licensing and partnership deals through 2026.

• No plans to expand headcount in 2026; commercial and digital teams are in place to support growth and partner engagement.

Market Opportunity and Clinical Impact

• U.S. diabetic kidney disease market includes 32 million diabetics and 30 million prediabetics, with PromarkerD able to predict risk up to four years in advance.

• Early detection enables use of renal-protective drugs, improving patient outcomes and reducing healthcare costs.

• Endometriosis test offers a non-invasive alternative to surgery, addressing a major gap in current care and attracting global interest.

• Esophageal cancer test provides a less invasive option than endoscopy, recently launched in Australia with U.S. launch pending.

• OxiDx test targets muscle damage and performance, with applications in sports medicine and animal welfare.